Paclitaxel-carboplatin an adjuvant chemo alternative for women with operable TNBC
02 Oct 2020
byAudrey Abella
A paclitaxel-carboplatin (PCb) regimen may be an alternative adjuvant chemotherapeutic strategy for women with operable triple-negative breast cancer (TNBC), given its greater benefit over a conventional regimen comprising cyclophosphamide, epirubicin, and fluorouracil, followed by docetaxel (CEF-T), the phase III PATTERN* trial has shown.